NZ334953A - Vitronectin receptor antagonists based upon benzodiazepinyl core structures useful in the treatment of osteoporosis, angiogenesis, tumour growth and metastasis, atherosclerosis, restenosis and inflammation - Google Patents
Vitronectin receptor antagonists based upon benzodiazepinyl core structures useful in the treatment of osteoporosis, angiogenesis, tumour growth and metastasis, atherosclerosis, restenosis and inflammationInfo
- Publication number
- NZ334953A NZ334953A NZ334953A NZ33495397A NZ334953A NZ 334953 A NZ334953 A NZ 334953A NZ 334953 A NZ334953 A NZ 334953A NZ 33495397 A NZ33495397 A NZ 33495397A NZ 334953 A NZ334953 A NZ 334953A
- Authority
- NZ
- New Zealand
- Prior art keywords
- benzodiazepinyl
- restenosis
- osteoporosis
- metastasis
- angiogenesis
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 102100022337 Integrin alpha-V Human genes 0.000 title abstract 2
- 206010027476 Metastases Diseases 0.000 title abstract 2
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 108010048673 Vitronectin Receptors Proteins 0.000 title abstract 2
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 230000009401 metastasis Effects 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 208000037803 restenosis Diseases 0.000 title abstract 2
- 230000004614 tumor growth Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2732096P | 1996-10-02 | 1996-10-02 | |
| US4377697P | 1997-04-11 | 1997-04-11 | |
| PCT/US1997/018001 WO1998014192A1 (en) | 1996-10-02 | 1997-10-01 | Vitronectin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ334953A true NZ334953A (en) | 2000-01-28 |
Family
ID=26702318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ334953A NZ334953A (en) | 1996-10-02 | 1997-10-01 | Vitronectin receptor antagonists based upon benzodiazepinyl core structures useful in the treatment of osteoporosis, angiogenesis, tumour growth and metastasis, atherosclerosis, restenosis and inflammation |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP0957917B1 (https=) |
| JP (2) | JP4491072B2 (https=) |
| KR (1) | KR100589578B1 (https=) |
| CN (1) | CN1114403C (https=) |
| AP (1) | AP1463A (https=) |
| AR (1) | AR008878A1 (https=) |
| AT (1) | ATE312089T1 (https=) |
| AU (1) | AU733417B2 (https=) |
| BG (1) | BG64581B1 (https=) |
| BR (1) | BR9712248B1 (https=) |
| CA (1) | CA2267224C (https=) |
| CO (1) | CO4900046A1 (https=) |
| CY (1) | CY2576B1 (https=) |
| CZ (1) | CZ299076B6 (https=) |
| DE (1) | DE69734833T2 (https=) |
| DK (1) | DK0957917T3 (https=) |
| DZ (1) | DZ2320A1 (https=) |
| EA (1) | EA002419B1 (https=) |
| ES (1) | ES2252775T3 (https=) |
| HU (1) | HU229221B1 (https=) |
| ID (1) | ID19623A (https=) |
| IL (1) | IL129243A (https=) |
| MA (1) | MA24361A1 (https=) |
| MY (1) | MY137606A (https=) |
| NO (1) | NO320194B1 (https=) |
| NZ (1) | NZ334953A (https=) |
| PE (1) | PE10499A1 (https=) |
| PL (1) | PL190859B1 (https=) |
| RO (1) | RO119881B1 (https=) |
| SA (1) | SA98180936B1 (https=) |
| SK (1) | SK285029B6 (https=) |
| TR (1) | TR199900737T2 (https=) |
| TW (1) | TW487702B (https=) |
| UA (1) | UA60311C2 (https=) |
| UY (2) | UY24735A1 (https=) |
| WO (1) | WO1998014192A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
| TW527355B (en) | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
| CN1273529A (zh) * | 1997-09-24 | 2000-11-15 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
| AU9578798A (en) * | 1997-09-24 | 1999-04-12 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
| US6372719B1 (en) | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| DE19842415A1 (de) * | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| AU2592600A (en) * | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| AU747503B2 (en) * | 1999-02-03 | 2002-05-16 | Merck & Co., Inc. | Benzazepine derivatives as alpha-V integrin receptor antagonists |
| JP5127096B2 (ja) * | 1999-04-30 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用 |
| AU6523200A (en) * | 1999-08-06 | 2001-03-05 | Smithkline Beecham Corporation | Vitronectin receptor antagonists useful for the treatment of strokes |
| US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| DE10028575A1 (de) | 2000-06-14 | 2002-03-14 | Basf Ag | Integrinliganden |
| DE10027514A1 (de) * | 2000-06-06 | 2002-01-03 | Basf Ag | Liganden von Integrinrezeptoren |
| FR2806082B1 (fr) * | 2000-03-07 | 2002-05-17 | Adir | Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2436130A1 (en) | 2001-01-29 | 2002-08-08 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted indoles and their use as integrin antagonists |
| KR20030087069A (ko) * | 2001-04-10 | 2003-11-12 | 스미스클라인 비참 코포레이션 | 유착 형성을 억제하는 방법 |
| SE0101386D0 (sv) | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | New compounds |
| WO2002090325A2 (en) * | 2001-05-03 | 2002-11-14 | Merck & Co., Inc. | Benzazepinone alpha v integrin receptor antagonists |
| EP1443963B1 (en) | 2001-10-22 | 2014-05-21 | The Scripps Research Institute | Antibody targeting compounds |
| GB0215867D0 (en) * | 2002-07-09 | 2002-08-14 | Glaxosmithkline Spa | Novel method and compounds |
| WO2004089890A2 (en) * | 2003-04-04 | 2004-10-21 | Smithkline Beecham Corporation | Process and intermediates for preparing benzazepines |
| AU2005229015C1 (en) * | 2004-04-02 | 2013-01-17 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| AU2012216372B2 (en) * | 2004-04-02 | 2015-01-22 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| AR052823A1 (es) * | 2004-12-21 | 2007-04-04 | Smithkline Beecham Corp | Uso de un antagonista del receptor de vitronectina para l a preparacion de una formulacion farmaceutica util para inhibir el exceso de formacion de cicatrices en la piel de a un mamifero y dicha formulacion |
| EA016227B1 (ru) * | 2005-11-29 | 2012-03-30 | Смитклайн Бичем Корпорейшн | Способ лечения офтальмологических неоваскулярных расстройств |
| EP2730282A1 (en) | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| AU2008321770B2 (en) * | 2007-11-16 | 2012-09-06 | Ube Industries, Ltd. | Benzazepinone compound |
| US8076475B2 (en) * | 2008-03-06 | 2011-12-13 | Glaxosmithkline Llc | Process |
| JP2012517447A (ja) | 2009-02-10 | 2012-08-02 | ザ スクリプス リサーチ インスティチュート | 化学的にプログラムされたワクチン接種法 |
| AU2010231631A1 (en) * | 2009-03-30 | 2011-11-10 | Ube Industries, Ltd. | Pharmaceutical composition for treatment or prevention of ophthalmic diseases |
| JP5572996B2 (ja) * | 2009-05-15 | 2014-08-20 | 宇部興産株式会社 | ベンズアゼピノン化合物を有効成分として含有する医薬 |
| EP2456460A4 (en) | 2009-07-24 | 2013-02-20 | Univ California | METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN |
| WO2011062765A2 (en) | 2009-11-17 | 2011-05-26 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| EP2325194A1 (en) * | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
| ES2864079T3 (es) | 2014-05-30 | 2021-10-13 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos |
| JP7693709B2 (ja) * | 2020-04-26 | 2025-06-17 | ジャンスー・エンファ・ファーマシューティカル・カンパニー・リミテッド | １，５－ジヒドロ－２，４－ベンゾジアゼピン－３－オン誘導体及びその使用 |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2197160T3 (es) * | 1992-12-21 | 2004-01-01 | Smithkline Beecham Corp | Antagonistas fibronogeno bicicliclos. |
| NZ290008A (en) * | 1994-06-29 | 1998-08-26 | Smithkline Beecham Corp | Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle |
| ZA955391B (en) * | 1994-06-29 | 1996-02-09 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| JPH10504825A (ja) * | 1994-08-22 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | 二環式化合物 |
| WO1996026190A1 (en) * | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
-
1997
- 1997-01-10 UA UA99031739A patent/UA60311C2/uk unknown
- 1997-09-29 DZ DZ970170A patent/DZ2320A1/xx active
- 1997-09-30 MA MA24817A patent/MA24361A1/fr unknown
- 1997-09-30 MY MYPI97004552A patent/MY137606A/en unknown
- 1997-10-01 SK SK425-99A patent/SK285029B6/sk not_active IP Right Cessation
- 1997-10-01 TR TR1999/00737T patent/TR199900737T2/xx unknown
- 1997-10-01 EP EP97909979A patent/EP0957917B1/en not_active Expired - Lifetime
- 1997-10-01 EA EA199900356A patent/EA002419B1/ru not_active IP Right Cessation
- 1997-10-01 HU HU9903769A patent/HU229221B1/hu not_active IP Right Cessation
- 1997-10-01 IL IL12924397A patent/IL129243A/en not_active IP Right Cessation
- 1997-10-01 PL PL332674A patent/PL190859B1/pl unknown
- 1997-10-01 CZ CZ0113299A patent/CZ299076B6/cs not_active IP Right Cessation
- 1997-10-01 AP APAP/P/1999/001493A patent/AP1463A/en active
- 1997-10-01 CN CN97180168A patent/CN1114403C/zh not_active Expired - Fee Related
- 1997-10-01 BR BRPI9712248-3A patent/BR9712248B1/pt not_active IP Right Cessation
- 1997-10-01 DE DE69734833T patent/DE69734833T2/de not_active Expired - Lifetime
- 1997-10-01 AU AU47462/97A patent/AU733417B2/en not_active Ceased
- 1997-10-01 AT AT97909979T patent/ATE312089T1/de active
- 1997-10-01 ID IDP973335A patent/ID19623A/id unknown
- 1997-10-01 CO CO97057225A patent/CO4900046A1/es unknown
- 1997-10-01 RO RO99-00353A patent/RO119881B1/ro unknown
- 1997-10-01 KR KR1019997002811A patent/KR100589578B1/ko not_active Expired - Fee Related
- 1997-10-01 WO PCT/US1997/018001 patent/WO1998014192A1/en not_active Ceased
- 1997-10-01 NZ NZ334953A patent/NZ334953A/xx not_active IP Right Cessation
- 1997-10-01 CA CA002267224A patent/CA2267224C/en not_active Expired - Fee Related
- 1997-10-01 ES ES97909979T patent/ES2252775T3/es not_active Expired - Lifetime
- 1997-10-01 PE PE1997000876A patent/PE10499A1/es not_active Application Discontinuation
- 1997-10-01 DK DK97909979T patent/DK0957917T3/da active
- 1997-10-01 JP JP51694298A patent/JP4491072B2/ja not_active Expired - Fee Related
- 1997-10-01 UY UY24735A patent/UY24735A1/es not_active IP Right Cessation
- 1997-10-02 AR ARP970104549A patent/AR008878A1/es active IP Right Grant
-
1998
- 1998-02-10 TW TW086114545A patent/TW487702B/zh not_active IP Right Cessation
- 1998-03-01 SA SA98180936A patent/SA98180936B1/ar unknown
- 1998-03-25 UY UY24935A patent/UY24935A1/es not_active IP Right Cessation
-
1999
- 1999-03-31 NO NO19991590A patent/NO320194B1/no not_active IP Right Cessation
- 1999-03-31 BG BG103299A patent/BG64581B1/bg unknown
-
2007
- 2007-05-18 CY CY0700010A patent/CY2576B1/xx unknown
-
2009
- 2009-10-09 JP JP2009235447A patent/JP2010006838A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ334953A (en) | Vitronectin receptor antagonists based upon benzodiazepinyl core structures useful in the treatment of osteoporosis, angiogenesis, tumour growth and metastasis, atherosclerosis, restenosis and inflammation | |
| IL147803A0 (en) | 28-epirapalogs | |
| AU7830398A (en) | Human tumor necrosis factor receptor tr9 | |
| SG82062A1 (en) | Control panel having sheet-formed pushbutton unit and method of producing the same | |
| AP2000001898A0 (en) | Vitronectin receptor antagonists | |
| PL334012A1 (en) | Novel method of treating the arthritis | |
| ZA200107865B (en) | Process for the preparation of discrete particles of calcium carbonate. | |
| ZA983376B (en) | Process for the preparation of flupirtine maleate. | |
| MXPA03004614A (es) | Material estabilizado de crepado posterior y metodo para producir el mismo. | |
| MXPA03000984A (es) | Metodos para el tratamiento del cancer y el dolor asociado con el mismo utilizando antagonistas de endotelina. | |
| HUP9700661A3 (en) | Use of alpha-1-adrenoreceptor antagonists for the production of pharmaceuticals for profilacting and treating cancer | |
| IL137954A0 (en) | Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia | |
| ZA989036B (en) | Methods and compositions for treating rheumatoid arthritis. | |
| AU5571298A (en) | Process, equipment and stone-processing line for the production of tiles of artificial or natural stone especially marble | |
| HUP0201508A2 (en) | Granular water-dispersible agents and process for producing the same | |
| HUP0003566A3 (en) | Process for producing dosage form and the obtained product | |
| ZA986294B (en) | Material for the production of building materials or shaped articles. | |
| AU3628800A (en) | Human tumor necrosis factor receptor tr9 | |
| HU9904564D0 (en) | Substituted cycloheptenes, process for producing them and their use | |
| EP0978553A4 (en) | HIGHLY CONCENTRATED WATER / SOLID MATERIAL SUSPENSION AND MANUFACTURING METHOD THEREOF | |
| MXPA03003907A (es) | Material no tejido y metodo para producirlo. | |
| IT1321155B1 (it) | Impianto per la produzione e la distribuzione controllata di energiaelettrica in zone isolate . | |
| ZA991779B (en) | A process for preparing endothelin receptor antagonists of the sulfanyl type. | |
| AU1310201A (en) | Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen | |
| ZA979655B (en) | Conjugates useful in the treatment of prostate cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |